Results 201 to 210 of about 87,574 (284)

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study. [PDF]

PLoS One
Ghia D, Thota P, Ritchie T, Rana H, Minhas R, Moolji J, Ritchie B, Adatia A.   +7 more
europepmc   +1 more source

Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. [PDF]

J Scleroderma Relat Disord, 2023
Cacciapaglia F, Stano S, Fornaro M, Iannone F.   +3 more
europepmc   +1 more source

Serum Proteomic Signatures of RA Risk and Response: Analysis of the APIPPRA Trial

Arthritis &Rheumatology, Accepted Article.
Objective To identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA study participants were selected from baseline to RA onset for 46 RA progressors or to study end for 72 participants who did not develop RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review. [PDF]

J Clin Med
Dimou M, Vacca A, Sánchez-Ramón S, Karakulska-Prystupiuk E, Lionikaite V, Siffel C, Anderson-Smits C, Kamieniak M.   +7 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly). [PDF]

Allergy Asthma Clin Immunol
Grosse-Kreul D, Allen C, Kalicinsky C, Keith PK.   +3 more
europepmc   +1 more source

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig^®]) in the treatment of patients with primary immunodeficiencies. [PDF]

Front Immunol, 2022
Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J.   +10 more
europepmc   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

BMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim, Hak Yong Kim, Ja Hoon Koo, Gi Doo Cha, Dae‐Hyeong Kim, Hye Jin Kim   +5 more
wiley   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source